

## COMPANY PROFILE

STRATEC designs and manufactures fully automated analyzer systems and smart consumables on the basis of its own patented technologies for its partners in clinical diagnostics and the life sciences industry. The company also provides sample preparation solutions and integrated laboratory software for these applications.

STRATEC can draw on a wealth of experience and an extensive technology pool to offer its partners automation and instrumentation technologies and solutions, as well as software development and sample preparation services.

Its services include joint definition of specifications, the entire development process, production, quality assurance, and preparations for approval by the relevant authorities in the target markets. Both existing technologies and newly developed solutions are consistently adapted in terms of their design to conform to partners' own corporate design schemes.

## SHARE CHART



## SHAREHOLDER STRUCTURE

Investor group	Share
Fixed and family ownership (incl. investment companies)	41.47%
Treasury shares	0.06%
Institutional investors	36.72%
Retail investors including not identified institutional investors	21.75%
Total	100.00%

## MANAGEMENT BOARD



Marcus Wolfinger



Dr. Robert Siegle



Dr. Claus Vielsack

## SUPERVISORY BOARD

> Fred K. Brückner

> Rainer Baule

> Prof. Dr. Stefanie Remmele

## STOCK FUNDAMENTALS

ISIN	DE000STRA555
WKN	STRA55
Symbol	SBS
Reuters Code	SBSG.DE
Branch	DAXsector All Pharma & Healthcare
Transparency level	Prime Standard
Market segment	Regulated Market
Type of shares	Registered Shares
Capital stock	11,913,445 Euro
No. of shares	11,913,445
Initial listing	Aug 25, 1998
Stock exchanges	Xetra; Frankfurt am Main and other regional exchanges in Germany

## FINANCIAL CALENDAR

<b>Nov 28, 2017</b>	German Equity Forum Organized by: Deutsche Börse - Analysts' Conference -
<b>Apr 19, 2018</b>	Publication annual financial report
<b>May 15, 2018</b>	Publication quarterly statement (call-date Q1)
<b>May 30, 2018</b>	Annual General Meeting
<b>Jul 24, 2018</b>	Publication half-yearly financial report
<b>Nov 08, 2018</b>	Publication quarterly statement (call-date Q3)
<b>Nov 27, 2018</b>	Analysts' Conference

## ANNUAL FIGURES

IFRS (in € million)	2012	2013	2014	2015	2016
Sales	122.7	128.0	144.9	146.9	184.9
EBIT	15.6	19.5	24.1	26.9	32.3
EBIT as % of sales	12.7	15.2	16.6	18.3	17.5
Consolidated net income	12.5	15.5	19.8	22.1	25.4
Basic earnings per share (in €)	1.06	1.32	1.68	1.87	2.14
Dividend per share (in €)	0.56	0.60	0.70	0.75	0.77
Total employees	533	546	544	583	976
Total assets	108.5	117.8	137.8	158.9	258.0
Equity ratio (in %)	80.7	82.5	81.3	82.0	55.7
Free cash flow	0.4	13.5	32.9	17.3	-

## QUARTERLY FIGURES

IFRS (in € thousand)	2017			2016		
	Q1	H1	9M	Q1	H1	9M
Sales	49,510	100,723	151,067	31,218	78,032	126,334
EBIT <sup>1</sup>	6,870	12,852	23,973	4,530	12,616	18,391
EBIT as % of sales <sup>1</sup>	13.9	12.8	15.9	14.5	16.2	14.6
Consolidated net income <sup>1</sup>	5,369	9,948	18,627 <sup>3</sup>	3,424	10,312	15,251 <sup>2</sup>
Basic earnings per share (in €) <sup>1</sup>	0.45	0.84	1.57	0.29	0.87	1.29

<sup>1</sup>Adjusted to exclude items relating to acquisition activities

<sup>2</sup>Additionally adjusted to exclude one-off items resulting from tax audit performed for 2009 to 2013 assessment periods

<sup>3</sup>Additionally adjusted to exclude deferred tax benefits resulting from loss carry forwards at companies acquired in 2016

**STRATEC Biomedical AG**

Gewerbestr. 37  
75217 Birkenfeld  
Germany

Phone: +49 7082 7916-0  
Fax: +49 7082 7916-999  
ir@strattec.com  
www.strattec.com

**Investor Relations**

Phone: +49 7082 7916-6515  
Fax: +49 7082 7916-9190  
ir@strattec.com